MidWestOne Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

MidWestOne Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-612	Closed	-$249K	–	302
2023 Q4	$249K	Sell	612 -1,040	-63%	-$384K	0.05%	257
2023 Q3	$574K	Sell	1,652 -544	-25%	-$190K	0.13%	177
2023 Q2	$773K	Buy	2,196 +184	+9%	+$62K	0.17%	159
2023 Q1	$634K	Sell	2,012 -2,238	-53%	-$671K	0.14%	166
2022 Q4	$1.23M	Sell	4,250 -484	-10%	-$148K	0.27%	82
2022 Q3	$1.37M	Sell	4,734 -364	-7%	-$105K	0.35%	59
2022 Q2	$1.44M	Sell	5,098 -112	-2%	-$30K	0.36%	59
2022 Q1	$1.36M	Sell	5,210 -1,617	-24%	-$384K	0.29%	80
2021 Q4	$1.5M	Buy	6,827 +4,082	+149%	+$794K	0.31%	75
2021 Q3	$498K	Buy	+2,745	New	+$536K	0.12%	161

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

MidWestOne Financial Group's VRTX Position: Q1 2024 in Review

MidWestOne Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 612 shares — an estimated $249K sold.

MidWestOne Financial Group first reported a position in VRTX in Q3 2021 and held it in 10 quarters. The position peaked at $1.5M in Q4 2021. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

MidWestOne Financial Group reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
MidWestOne Financial Group sold 612 Vertex Pharmaceuticals shares in Q1 2024, an estimated $249K.
MidWestOne Financial Group first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 10 quarters.
MidWestOne Financial Group's Vertex Pharmaceuticals position peaked at $1.5M in Q4 2021.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on MidWestOne Financial Group's 13F filing for Q1 2024, filed 15 May 2024.